QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:GMDA

Gamida Cell (GMDA) Competitors

$0.91
-0.06 (-6.28%)
(As of 05:37 PM ET)
Compare
Today's Range
$0.88
▼
$1.00
50-Day Range
$0.97
▼
$1.55
52-Week Range
$0.56
▼
$2.51
Volume
1.95 million shs
Average Volume
2.61 million shs
Market Capitalization
$96.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

GMDA vs. JATT, TSBX, TCRX, VXRT, TALS, GRPH, KOD, ORTX, CCCC, and OCGN

Should you be buying Gamida Cell stock or one of its competitors? The main competitors of Gamida Cell include JATT Acquisition (JATT), Turnstone Biologics (TSBX), TScan Therapeutics (TCRX), Vaxart (VXRT), Talaris Therapeutics (TALS), Graphite Bio (GRPH), Kodiak Sciences (KOD), Orchard Therapeutics (ORTX), C4 Therapeutics (CCCC), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry.

Gamida Cell vs.

JATT Acquisition (NYSE:JATT) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, community ranking, institutional ownership, risk, valuation, analyst recommendations and earnings.

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 42.7% of Gamida Cell shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 3.4% of Gamida Cell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Gamida Cell had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Gamida Cell and 0 mentions for JATT Acquisition. Gamida Cell's average media sentiment score of 0.00 beat JATT Acquisition's score of -0.50 indicating that JATT Acquisition is being referred to more favorably in the media.

Company Overall Sentiment
JATT Acquisition Neutral
Gamida Cell Negative

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JATT AcquisitionN/AN/A$6.85MN/AN/A
Gamida CellN/AN/A-$79.38M-$0.58-1.57

Gamida Cell's return on equity of -49.58% beat JATT Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
JATT AcquisitionN/A -49.58% 2.84%
Gamida Cell N/A -827.43%-81.65%

Gamida Cell has a consensus price target of $7.60, suggesting a potential upside of 735.16%. Given JATT Acquisition's higher possible upside, analysts plainly believe Gamida Cell is more favorable than JATT Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JATT Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Gamida Cell
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Gamida Cell received 108 more outperform votes than JATT Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
JATT AcquisitionN/AN/A
Gamida CellOutperform Votes
108
68.35%
Underperform Votes
50
31.65%

Summary

JATT Acquisition beats Gamida Cell on 6 of the 10 factors compared between the two stocks.


Get Gamida Cell News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GMDA vs. The Competition

Export to Excel
MetricGamida CellBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$96.05M$2.62B$4.29B$6.26B
Dividend YieldN/A2.25%2.40%5.88%
P/E Ratio-1.574.27112.1612.26
Price / SalesN/A132.532,881.7469.54
Price / CashN/A25.2087.00101.50
Price / Book-8.273.493.724.71
Net Income-$79.38M$55.98M$121.24M$185.55M
7 Day Performance-20.21%0.37%-2.08%-3.28%
1 Month Performance-26.05%-4.55%-0.80%-4.35%
1 Year Performance-55.41%-1.15%5.31%1.37%

Gamida Cell Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JATT
JATT Acquisition
0 of 5 stars		$7.03
+4.5%		N/A-42.7%$121.27MN/A0.002,021High Trading Volume
TSBX
Turnstone Biologics
1.7885 of 5 stars		$5.37
-31.3%		$19.00
+253.8%		N/A$122.66M$39.97M0.00108Gap Down
TCRX
TScan Therapeutics
2.1358 of 5 stars		$2.62
+0.8%		$11.50
+338.9%		+0.7%$125.29M$16.41M-0.91135Gap Down
VXRT
Vaxart
1.6111 of 5 stars		$0.77
-2.5%		$2.75
+257.0%		-67.9%$117.08M$2.06M-1.01164News Coverage
TALS
Talaris Therapeutics
1.8117 of 5 stars		$2.68
-5.0%		$7.50
+179.9%		-6.5%$114.61MN/A0.0084Positive News
GRPH
Graphite Bio
1.8827 of 5 stars		$2.22
+1.8%		$3.33
+50.2%		-26.8%$128.72MN/A-0.97120Short Interest ↑
KOD
Kodiak Sciences
2.7011 of 5 stars		$2.17
-2.3%		$7.33
+237.9%		-77.5%$113.82MN/A-0.38118Positive News
ORTX
Orchard Therapeutics
2.0944 of 5 stars		$4.94
+2.3%		$24.50
+396.0%		+56.0%$112.25M$21.31M-1.10166
CCCC
C4 Therapeutics
1.5463 of 5 stars		$2.26
-4.6%		$10.13
+348.0%		-76.4%$111.17M$16.03M-0.79146Short Interest ↑
News Coverage
Positive News
Gap Down
OCGN
Ocugen
1.6293 of 5 stars		$0.42
flat		$3.50
+733.3%		-81.0%$107.73M$42.62M-1.1484News Coverage

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:GMDA) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -